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Abstract Cell lines transfected with the Swedish Alzheimer’s disease amyloid precursor protein APP6701671 mutation release significantly more 
B-amyloid than wild-type cells. Citron et al. [Proc. Natl. Acad. Sci. USA (1994) in press] have recently shown that fibroblasts carrying the APP670/671 
mutation also release more /3-amyloid than control cells [l]. The present study confirms a ca. threefold increase in /3-amyloid release from 
mutation-bearing fibroblasts. APP mRNA levels did not differ between mutation-bearing and control cells, although mutation-bearing fibroblasts 
contained significantly more APP751/770 than controls. Mild stress decreased B-amyloid secretion and increased APP751/770 levels in all cell lines. 
In conclusion, the proportion of APP committed to amyloidogenic processing is increased in fibroblasts from family members with the APP670/671 
mutation, and this mutation may also compromise the APP stress response. 
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1. Intioduction 
Alzheimer’s disease is a progressive neurodegenerative disor- 
der defined histopathologically by the excessive accumulation 
of extracellular proteinaceous deposits (amyloid plaques) and 
intraneuronal bundles of paired helical filaments (neurofibril- 
lary tangles) throughout the hippocampus and neocortex. A 
39-43 amino acid peptide, termed /3-amyloid, has been identi- 
fied as the major constituent of plaque and cerebrovascular 
amyloid [2]. This peptide is a metabolite of the amyloid precur- 
sor protein (APP), encoded by a gene on chromosome 21 [3]. 
The identification of pathogenic APP gene mutations in some 
Alzheimer’s disease families has firmly established the impor- 
tance of APP and /3-amyloid in the aetiology of this disorder 
[4,51. 
APP RNA is alternatively spliced in a tissue-specific manner, 
giving rise to at least ten different mRNA species. These include 
APP770 with domains showing homology to a Kunitz type 
protease inhibitor (KPI) and the MRC OX-2 antigen; APP751 
which includes the KPI region only; and APP695 which lacks 
both the KPI and the MRC OX-2 domains [3,&8]. 
Two alternative APP processing routes utilising the as yet 
unidentified enzymes, a- and p-secretase, have been identified. 
asecretase cleaves APP at amino-acid 16 of the/?-amyloid pep- 
tide, just outside the APP transmembrane domain [9,10]. Me- 
tabolism along this route results in the release of the amino 
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terminal portion of APP and precludes the generation of full- 
length /%amyloid. The detection of soluble /?-amyloid in the 
medium of normal cells in culture [I 1,121 and in the CSF of 
healthy individuals [13] revealed the presence of thep-secretase 
pathway operating in parallel to the non-amyloidogenic a-se- 
cretase processing. /?-Secretase cleaves APP between Met-671 
and Asp-672 (APP770 numbering) to generate a secreted amino 
terminal APP metabolite and leaving full-length B-amyloid in 
a membrane-associated carboxy-terminal fragment. The mech- 
anisms of further processing of the carboxy-terminal fragment 
to produce extracellular B-amyloid are not clearly defined, but 
have been proposed to occur intracellularly in an acidic com- 
partment, possibly in early endosomes [14,151. 
We have identified a double mutation in the APP gene result- 
ing in amino acid substitutions of Lys to Asn (codon 670) and 
Met to Leu (671) in a large Swedish family where Alzheimer’s 
disease is inherited in an autosomal dominant manner [5,16]. 
Subsequently, it was shown that human kidney 293 and neu- 
roblastoma Ml7 cell lines transfected with this mutation re- 
leased approximately 7 times more /?-amyloid into culture me- 
dium than their wild type counterparts [17,18]. Recently, Citron 
et al. have shown that /?-amyloid release is increased in fibro- 
blast cell lines from Swedish APP670/671 mutation carriers, 
co’mpared to control family members [I]. 
In the present study, we quantified B-amyloid release from 
primary fibroblast cell lines established from heterozygous 
APP670/671 mutation carriers and control family members 
using a sensitive ELISA assay [13]. In addition, we examined 
the influence of this mutation on APP mRNA and protein 
levels in these cell lines. The effects of a mild stress, in the form 
of a 20 h serum deprivation, on cellular APP levels and 
/%amyloid release was also investigated. 
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2. Materials and methods bating blots for 1 h in 20 mM Tris-HCl (pH 7.6), 137 mM NaCl, and 
0.1% Tween 20 (TBS-T) with 5% non-fat dried milk. Blots were rinsed 
in TBS-T prior to incubation for 3 h at room temperature with the 
monoclonal antibody 22Cll (1:10,000 dilution), raised against full- 
length APP695 [24]. Blots were rinsed again prior to the addition of the 
secondary antibody, HRP-linked anti-mouse IgG (1:2000 dilution) for 
1 h, and rinsed thoroughly overnight before detection of immunoreac- 
tivity using the enhanced chemiltinescence (ECL) detection system 
(Amersham, UK), followed by exposure to Hyperfihn MP (Amersham, 
UK). The cell lysates were run in two different ways. Firstly, cell lysates 
from family members with and without the mutation were age matched 
and run in adjacent lanes. Secondly, the same cell line maintained in 
the presence or absence of serum was run in adjacent lanes. Each cell 
lysate was run at least three times. Levels of APP immunoreactivity 
were quantified by densitometric analysis of the autoradiograms using 
an IBAS image analysis system (Zeiss). The data was expressed as 
absolute mean grey density values obtained from the analysis of three 
separate autoradiograms. 
2.1. Cell culture 
Fibroblast cell lines were established from upper arm skin biopsies 
taken from 12 informed family members. Cells were grown in two 
groups with three mutation-bearing and three control lines in each 
group. The cell lines were age matched, mean age f S.E.M. being 
55 f 3.7 for the familv members with the mutation and 59 + 2.6 for the 
controls. Three of the-family members with the mutation had developed 
symptoms of Alzheimer’s disease, whereas the other three were asymp- 
tomatic. 
Fibroblasts were grown in minimum essential medium with Earle’s 
salts containing 10% heat-inactivated foetal calf serum (FCS), 2 mM 
L-glutamine, 100 units/ml penicillin, 100 &ml streptomycin and 60 
&ml Tylocine (Anti-PPLO agent) (Gibco-BRL, Life Technologies, 
European Division). Cells were passaged between 6 and 9 times and 
grown to near confluency before harvesting one 75 cm2 flask for APP 
immunoblotting and four 75 cm* flasks for RNA assay. 
The cells for RNA assay were maintained in medium containing 10% 
FCS throughout, harvested by trypsination and centrifuged at 400 x g 
for 15 min at room temperature. The pellet was snap frozen to - 135’C 
and stored at - 70°C. 
Prior to harvesting for APP immunoblotting, cells were washed in 
medium either with or without 10% FCS, and incubated in this medium 
for 20 h. The conditioned media was stored at -20°C prior to assay for 
/3-amyloid. Fibroblasts were harvested by washing twice with ice-cold 
Ca” and Mg*’ free PBS (Gibco-BRL), and scraping with a rubber 
policeman in 1.5 ml of the same buffer. Cells were collected by centrif- 
ugation at 600 x g for 15 min at 4°C and lysates prepared by adding 
200~1 of 40 mM Tris-HCl, 2% SDS, pH 6.8 to the pellet and sonicating 
for 12 s (amplitude 22 microns). The lysates were boiled for 3 min, and 
stored frozen at - 20°C prior to APP immunoblotting. Protein concen- 
tration was determined using the Pierce BCA protein assay kit (Pierce, 
USA). 
2.2. P-Amyloid assay 
B-Amyloid concentrations in conditioned media (15 ml per 75 cm* 
flask) were determined by enzyme-linked immunoassay (ELISA) em- 
ploying the 266 and 6C6 monoclonal antibodies directed against amino 
acids 13 to 28 and 1 to 16 of theg-amyloid peptide. The medium, which 
had been in contact with the cells for 20 h, was concentrated IO-fold 
by freeze-drying before assay as previously described [13]. 
2.3. RNA assay 
RNA was quantified using a sensitive RNA-RNA solution hybrid- 
isation assay [19,20] adapted for APP RNA (Johnston et al, in prep- 
aration). Briefly, a BumHI (position 99) to OnI (position 107) fragment 
spanning the exon l/2 boundary was digested from the cDNA pUCl2- 
APP695 and inserted into a pGEM3zf’ vector @omega). Radiola- 
belled ([“S]CTP, Amersham) anti-sense APP RNA probe and sense 
APP RNA standard were transcribed in vitro using T7 or SP6 RNA 
polymerase (Riboprobe Gemini II system, Promega). This probe hy- 
bridises to all reported APP RNA species. Hybridisation of probe with 
sense RNA enabled construction of a standard curve. Total nucleic acid 
(TNA) was prepared from the fibroblasts. TNA and DNA concentra- 
tions were determined spectrophotometrically and using Hoechst 33258 
fluorimetry, respectively [21]. Sense RNA or TNA extract were hy- 
bridised in solution with excess probe for 18 h at 68°C with 25% 
formamide, 0.75 mM DTT, 0.6 M NaCl, 20 mM Tris and 4 mM EDTA. 
Non-hybrid&d RNA was then degraded by the addition of RNase Tl 
(2 @ml), RNase A (40 pg/ml) and salmon sperm DNA (100 @ml). 
Ribonuclease-resistant hybrids were precipitated with 10% TCA, cap- 
tured on Whatman GF/C filters, washed twice with 4% TCA in 1% 
sodium pyrophosphate, once with 95% ethanol and quantified by scin- 
tillation counting. The equivalent amount of standard APP RNA (pg 
of 166 nucleotide transcripts) was calculated by comparison with the 
standard curve, and results expressed as pg APP RNA per pg RNA in 
the sample. 
2.4. Immunoblotting 
Three pg of protein from each sample of fibroblast cell lysate was 
separated by 8% SDS-PAGE [22]. Proteins were transferred electro- 
phoretically (200 V, 2 h) to nitrocellulose membranes (Schleicher and 
Schuell, 0.45 pm) [23]. Non-specific binding sites were blocked by incu- 
3. Results 
Fig. 1 shows the p-amyloid levels detected in conditioned 
media. Medium conditioned by mutation-bearing fibroblasts 
contained ca. 2.7 times more B-amyloid than medium condi- 
tioned by control cells in the presence of serum, and ca. 3.5 
times more in the absence of serum. There was no difference 
in the j?-amyloid levels in mutation-bearing cells derived from 
individuals who had developed symptoms of Alzheimer’s dis- 
ease and those who were under the age of disease onset. Inter- 
estingly, Fig. 1 also shows that the levels ofSamyloid detected 
in serum free medium were approximately 50% of those de- 
tected in the presence of serum. 
There was no significant difference in the level of APP RNA 
in mutation-bearing and control fibroblasts. The level of APP 
RNA, expressed as equivalent pg standard APP RNA&g total 
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Fig. 1. /?-Amyloid levels detected by ELISA of concentrated condi- 
tioned media from mutation-bearing and control cell lines maintained 
in the presence and absence of 10% foetal calf serum. Mean values are 
represented by a horizontal bar. Significance levels are shown for the 
comparison of mutation bearing and control cells, ***P < 0.001 
**P c 0.01 (Student’s t-test). The levels of/?-amyloid were significantly 
lower in serum-free compared to serum-containing media for both 
mutation bearing and control cells, (P < 0.05, paired t-test). 
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Fig. 2. Representative autoradiogram of cell lysates from fibroblasts 
maintained inthe absence of semm for 20 h prior to harvesting. Muta- 
tion bearing (M) and control (C) cells are shown. 3 pg of protein from 
each cell line was separated by 8% SDS-PAGE and probed with the 
monoclonal antibody 22Cll as described in section 2. Molecular 
weights were determined by comparison with a pre-stained molecular 
weight standard mixture (Sigma SDS-7B). 
RNA in the sample, was 0.92 f 0.11 (mean f S.E.M.) in the 
mutation-bearing fibroblasts and 0.81 f 0.14 in the controls. 
Figs. 2 and 3 show representative immunoblots of control 
and APP670/67 1 mutation-bearing cell lysates. The 22C 11 an- 
tiserum recognised immunoreactive bands with relative mobili- 
ties corresponding to 134 kDa, 130 kDa, 118 kDa, 114 kDa, 
and a lower molecular weight band of 60 kDa. The most prom- 
inent bands were those of 118 and 114 kDa, which are consid- 
ered to represent comigratory full-length N-glycosylated 
APP75UAPP770 and APP695, respectively, with the fainter 
higher molecular weight bands representing the N- and O- 
glycosylated forms of these APP isoforms [24,25]. The 60 kDa 
band may be a shorter APP fragment. Densitometric analysis 
was performed on the 118 kDa and 114 kDa isoforms only, due 
to the lightness of the 134 and 130 kDa bands. Analysis of the 
autoradiogram shown in Fig. 2 revealed that the fibroblasts 
contained approximately three times more APP751/770 than 
APP695, although the APP7511770 band was dark, and at the 
limits of linearity for densitometry. Further results were there- 
fore generated by analysing the bands on separate autoradi- 
ograms with different exposure times so that both would be 
within the linear range for densitometry. Fig. 3 shows an 
autoradiogram with a shorter exposure time, used to analyse 
the APP751/770 band. 
The data obtained from the densitometric analyses is pre- 
sented in Table 1. These results revealed that in the presence 
of serum, mutation bearing cell lines contained significantly (ca. 
30%) higher levels of APP7511770 than controls (P < 0.05, Stu- 
dent’s t-test). Following a 20 h serum deprivation, APP751/770 
levels increased in both the mutation-bearing and control cell 
lines. This increase was statistically significant in the control 
cells where levels were ca. 30% higher in the absence of serum 
(P < 0.05, paired t-test). In contrast, the mutation-bearing cell 
lines had only 17% higher levels of APP751/770 after serum 
deprivation (0.05 < P < 0.1, paired t-test). Consequently, the 
mutation-related ifference in APP751/770 levels was less pro- 
nounced (ca. 18%) in the absence of serum (0.05 < P < 0.1, 
Student’s t-test). 
APP695 levels in these fibroblasts were not significantly af- 
fected by the presence of the mutation, or serum deprivation 
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(Table 1). However, some trends similar to those for APP751/ 
770 were seen, as mutation-bearing cell lines contained ca. 15% 
more APP695 than controls in the presence of serum. Serum 
deprivation resulted in a ca. 16% increase in APP695 levels in 
control cell lines, and this response was absent in mutation- 
bearing cells. 
4. Discussion 
This study shows that fibroblasts derived from family mem- 
bers with the Swedish Alzheimer’s disease APP670/671 muta- 
tion released approximately three times more p-amyloid into 
the culture medium than control fibroblasts. Recent cell trans- 
fection studies have shown that this mutation increases the 
proportion of APP committed to amyloidogenic processing 
[ 17,181. The Met to Leu conversion at codon 67 1 was sufficient 
to increase @myloid release, strongly implying that the prox- 
imity of this mutation to the amino terminus of the /I-amyloid 
peptide renders this cleavage site more susceptible to /3-secre- 
tase activity [17]. A recent investigation of /I-amyloid release 
from mutation-bearing fibroblast cell lines using metabolic la- 
belling and immunoprecipitation techniques detected an in- 
creased B-amyloid release from these more physiological cell 
lines [I]. These findings, and those of the present study, provide 
strong evidence that increased p-amyloid release is the underly- 
ing disease mechanism in the Swedish APP670/671 family, as 
initially suggested by the transfection studies [17,18]. 
Interestingly, we also found that the B-amyloid release from 
both mutation-bearing and control cells was reduced by ca. 
50% when cells were grown in serum free medium. Decreased 
p-amyloid release from Ml7 neuroblastoma nd human kidney 
293 cells following serum deprivation has recently been noted 
by other investigators [26,27]. 
The present study also identified a difference between 
APP751/770, but not APP695, levels in cell lysates of mutation- 
bearing, compared to control cell lines. Mutation bearing cells 
contained modestly (ca. 30%), but nonetheless significantly 
higher APP751/770 levels than control cells in the presence of 
serum. However, quantification of total APP RNA under these 
conditions did not reveal a corresponding increase in mutation 
bearing cells. Although we cannot disregard the possibility of 
altered RNA splicing in favour of the APP751/770 isoforms, 
this seems unlikely since no corresponding decrease in the level 
of APP695 (as detected by immunoblotting) was evident. The 
RNA data thus suggest hat the difference in protein levels is 
due to altered protein translation or processing. The mutation- 
Table 1 
Levels of APP75 11770 and APP695 in mutation-bearing and control cell 
lines maintained in the presence and absence of 10% foetal calf serum 
Mutation bearing cells Control cell lines 
Serum Serum-free Serum Serum free 
APP 7511770 83.3 f 1.5 97.3 f 6.1+ 63.5 f 7.0 82.3 + 4.6+ 
APP 695 28.2 f 4.5 26.7 + 3.3 24.5 f 3.7 28.3 f 2.9 
Data is expressed as mean optical density values ? S.E.M. from 
3 individual experiments performed as described in section 2. Significance 
levels are shown for the comparison of APP levels in cells maintained 
in serum-containing and serum-free media, *P < 0.05, ‘0.1 > P > 0.05 
(paired r-test). A significant difference was also seen for the comparison 
of APP751/770 levels in mutation-bearing and control cell lines main- 
tained in serum-containing medium (P < 0.05, Student’s t-test). 
J.A. Johnston et al. IFEBS Letters 354 (1994) 274-278 217 
MMC CMM 
MW (kDa) 
- 60 
Fig. 3. Representative autoradiograms of fibroblast lysates prepared 
from mutation-bearing (M) and control (C) cells maintained in the 
presence (+) or absence (-) of serum for 20 h prior to harvesting. 3 pg 
protein from each cell line was separated by 8% SDS-PAGE and probed 
with the monoclonal antibody 22Cll as described in section 2. The 
molecular weights were determined by comparison with a pre-stained 
molecular weight standard mixture (Sigma SDS-7B). 
related increase in/?-amyloid release may result in up-regulated 
APP translation in order to maintain physiological levels of 
full-length APP. 
We were also interested in investigating the effect of stress 
on full-length APP levels in these cells, since the promoter 
region of APP contains a stress response element [28]. A mild 
stress in the form of 20 h serum deprivation resulted in in- 
creased APP751/770 levels in both the mutation bearing and 
control cell lines, whilst APP695 levels were not significantly 
affected. A modest 17% increase in the level of APP751/770 was 
seen in mutation bearing cell lines, but the response was more 
marked and statistically significant in the control fibroblasts, 
where a ca. 30% increase was observed. Thus in the absence of 
serum, the difference in APP751/770 levels between mutation- 
bearing and control cell lines was reduced to ca. 18% (compared 
to 30% in the presence of serum) and lost statistical significance. 
This physiological response to stress may therefore be compro- 
mised in mutation-bearing cells, perhaps due to the slightly 
elevated basal levels of API? 
A 72 h serum deprivation has previously been shown to 
increase expression of APP751/770 and 695 in fibroblasts [29]. 
Our results confirm that a shorter period of serum deprivation 
is adequate to elicit a similar APP751/770 response. APP levels 
may increase either as a general response to the stress presented 
by serum starvation, or as a more specific response to the 
removal of a component of serum. Foetal calf serum is a com- 
plex mixture of proteins, polypeptides and growth factors, 
hormones, lipids, amino acids and minerals [30]. Several growth 
factors such as nerve, epidermal, and fibroblast growth factor 
are capable of altering APP expression and release [31,32]. 
Further experiments involving isolation of the potential active 
ingredients in serum and investigation of their individual effects 
on these cells are required in order to explore more fully the 
mechanism behind the increased APP751/770 levels and de- 
creased B-amyloid release in response to serum deprivation. 
In summary, this study of primary fibroblast cell lines de- 
rived from individuals carrying the APP670/671 mutation pro- 
vides strong evidence that increased p-amyloid release leads to 
the development of Alzheimer’s disease in the Swedish APP670/ 
671 family. Mutation-bearing fibroblasts derived from family 
members who were 5 to 10 years younger than the predicted 
age of onset released as much &amyloid as cell lines from 
individuals who had developed symptoms of the disease, show- 
ing that this is an early event in the disease process. These 
fibroblast cell lines provide a useful model system to investigate 
mechanisms promoting accelerated amyloidosis and to screen 
for compounds capable of reducing p-amyloid production. 
These results also raise some crucial questions concerning the 
molecular basis of the selectivity of the disease symptoms, since 
peripheral cells are clearly also over-producing /I-amyloid. The 
observation that levels of full-length APP and the response of 
these fibroblasts to stress may be altered by the presence of the 
APP670/671 mutation is also worthy of further investigation. 
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